

# Antiemetic changes in treatment schedules

There have been recent changes to national and international guidelines. For further information refer to the eviQ 'Prevention of chemotherapy induced nausea and vomiting' document. [www.eviq.org.au/p/7](http://www.eviq.org.au/p/7)

## High emetogenic risk protocols

The netupitant/palonosetron combination has replaced aprepitant and a 5HT3 receptor antagonist in combination with dexamethasone for all highly emetogenic regimens.

ID	Protocol name
81	Anal Definitive cisPlatin and Fluorouracil Chemoradiation
1661	Bladder Adjuvant ddMVAC (Dose Dense Methotrexate vinBLASTine DOXOrubicin cisPlatin)
312	Bladder Locally Advanced or Metastatic cisPlatin and Gemcitabine
315	Bladder Metastatic MVAC (Methotrexate vinBLASTine DOXOrubicin cisPlatin)
1437	Bladder Neoadjuvant cisPlatin and Gemcitabine
1616	Bladder Neoadjuvant ddMVAC (Dose Dense Methotrexate vinBLASTine DOXOrubicin cisPlatin)
1438	Bladder Neoadjuvant MVAC (Methotrexate vinBLASTine DOXOrubicin cisPlatin)
1725	Bladder Small Cell cisPlatin and Etoposide
134	Breast Adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) Dose Dense
128	Breast Adjuvant AC (DOXOrubicin CYCLOPHOSPHamide) Three Weekly
683	Breast Adjuvant EC (Epirubicin and CYCLOPHOSPHamide)
136	Breast Adjuvant FEC (Fluorouracil Epirubicin CYCLOPHOSPHamide) (Part 1 of FEC-D)
27	Breast Adjuvant FEC 100 (Fluorouracil Epirubicin CYCLOPHOSPHamide)

13	Breast Adjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide)
18	Breast Metastatic AC (DOXOrubicin and CYCLOPHOSPHamide)
1306	Breast Metastatic EC (Epirubicin and CYCLOPHOSPHamide)
46	Breast Metastatic FEC (Fluorouracil Epirubicin CYCLOPHOSPHamide)
72	Breast Neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide)
1869	Breast Neoadjuvant Dose Dense AC (DOXOrubicin and CYCLOPHOSPHamide) (Part 2)
1623	Breast Neoadjuvant FEC (Fluorouracil Epirubicin CYCLOPHOSPHamide) (Part 1 of FEC-D)
1295	Breast Neoadjuvant TAC (DOCEtaxel DOXOrubicin CYCLOPHOSPHamide)
672	Endometrial Metastatic or Recurrent AP (DOXOrubicin cisPlatin)
1216	Gastric and Gastroesophageal Metastatic cisPlatin Capecitabine Trastuzumab
1217	Gastric and Gastroesophageal Metastatic cisPlatin Fluorouracil Trastuzumab
1214	Gastric and Oesophageal Metastatic cisPlatin Capecitabine
701	Gastric and Oesophageal Metastatic cisPlatin Fluorouracil
327	Gastric and Oesophageal Metastatic ECF (Epirubicin cisPlatin Fluorouracil) SUPERSEDED
526	Gastric and Oesophageal Metastatic ECX (Epirubicin cisPlatin Capecitabine) SUPERSEDED
326	Gastric and Oesophageal Neoadjuvant and Adjuvant ECF (Epirubicin cisPlatin Fluorouracil)
1675	Glioma High Grade Recurrent Carmustine
658	Head and Neck Salivary Gland Advanced CAP (CYCLOPHOSPHamide DOXOrubicin cisPlatin)
291	Head and Neck Squamous Cell Carcinoma Locally Advanced Definitive cisPlatin (Three Weekly) Chemoradiation
292	Head and Neck Squamous Cell Carcinoma Locally Advanced Definitive cisPlatin (Weekly) Chemoradiation

588	Head and Neck Squamous Cell Carcinoma Locally Advanced Induction TPF (DOCEtaxel cISplatin Fluorouracil) (Part 1)
286	Head and Neck Squamous Cell Carcinoma Locally Advanced Post Operative cISplatin (Three Weekly) Chemoradiation
287	Head and Neck Squamous Cell Carcinoma Locally Advanced Post Operative cISplatin (Weekly) Chemoradiation
288	Head and Neck Squamous Cell Carcinoma Recurrent or Metastatic cISplatin (Three Weekly) and Fluorouracil
1138	Head and Neck Squamous Cell Carcinoma Recurrent or Metastatic cISplatin Fluorouracil with Cetuximab
56	Hodgkin Lymphoma Advanced Stage ABVD (DOXOrubicin Bleomycin VinBLASTine Dacarbazine)
57	Hodgkin Lymphoma Early Stage ABVD (DOXOrubicin Bleomycin VinBLASTine Dacarbazine)
833	Lymphoma DHAP (Dexamethasone Cytarabine cISplatin)
1615	Lymphoma GDP (Gemcitabine Dexamethasone cISplatin)
1451	Lymphoma GIVE (G-CSF IFOSFamide Etoposide Epirubicin) SUPERSEDED
337	Malignant Melanoma Metastatic Dacarbazine
1884	Mantle Cell Lymphoma R-DHAP (RITUximab Dexamethasone Cytarabine cISplatin)
229	Mesothelioma cISplatin and Pemetrexed
1154	Nasopharyngeal Locally Advanced Adjuvant cISplatin and Fluorouracil (Following Chemoradiation)
277	Nasopharyngeal Locally Advanced cISplatin (Three Weekly) Chemoradiation
278	Nasopharyngeal Locally Advanced cISplatin (Weekly) Chemoradiation
1384	Nasopharyngeal Recurrent or Metastatic cISplatin and Gemcitabine
1220	Neuroendocrine Advanced cISplatin and Etoposide
237	Non Small Cell Lung Cancer Adjuvant cISplatin and vinORELBine
379	Non Small Cell Lung Cancer cISplatin and Etoposide Chemoradiation Definitive

1513	Non Small Cell Lung Cancer Locally Advanced cisPlatin and DOCETaxel Chemoradiation
227	Non Small Cell Lung Cancer Metastatic cisPlatin and DOCETaxel SUPERSEDED
1434	Non Small Cell Lung Cancer Metastatic cisPlatin and Gemcitabine (Day 1 cisPlatin)
262	Non Small Cell Lung Cancer Metastatic cisPlatin and Gemcitabine (Modified) (Day 8 cisPlatin) SUPERSEDED
88	Non Small Cell Lung Cancer Metastatic cisPlatin and Pemetrexed
239	Non Small Cell Lung Cancer Metastatic cisPlatin and vinORELBine
378	Non Small Cell Lung Cancer Superior Sulcus (Pancoast) cisPlatin and Etoposide Chemoradiation Pre-Operative
1584	Non-Hodgkin Lymphoma R-DHAP (RITUximab Dexamethasone Cytarabine cisPlatin)
2041	Oesophageal Definitive Chemoradiation cisPlatin and Fluorouracil followed by cisPlatin and Fluorouracil
1250	Oesophageal Neoadjuvant cisPlatin and Fluorouracil Chemoradiation
1901	Osteosarcoma MAP (Methotrexate, DOXOrubicin, cisPlatin)
265	Ovarian Advanced Combined Intravenous and Intraperitoneal cisPlatin and PACLitaxel
968	Primary CNS Lymphoma (PCNSL) (Methotrexate and Cytarabine)
1565	Primary CNS Lymphoma (PCNSL) High Dose Methotrexate
1716	Small Cell Lung Cancer Extensive Disease cisPlatin and Irinotecan
375	Small Cell Lung Cancer Limited Disease cisPlatin and Etoposide
376	Small Cell Lung Cancer Limited Disease cisPlatin and Etoposide Chemoradiation
1659	Soft Tissue Sarcoma Locally Advanced or Metastatic DOXOrubicin and IFOSFamide
316	Testicular Germ Cell Recurrent TIP (PACLitaxel IFOSFamide cisPlatin)

## Carboplatin AUC $\geq$ 4 protocols

A NK1 receptor antagonist and a 5HT3 receptor antagonist in combination with dexamethasone has been added as available on the PBS for primary prophylaxis of carboplatin induced nausea and vomiting.

ID	Protocol name
53	Breast adjuvant TCH (DOCEtaxel cARBOplatin trastuzumab)
1714	Breast neoadjuvant cARBOplatin and weekly PACLItaxel (part 1)
667	Cervical recurrent or metastatic cARBOplatin and PACLItaxel
708	Endometrial recurrent or metastatic cARBOplatin and PACLItaxel
1016	Ovarian advanced cARBOplatin three weekly and PACLItaxel weekly
1601	Ovarian advanced cARBOplatin, PACLItaxel and bevacizumab
251	Ovarian high risk stage 1 adjuvant cARBOplatin and PACLItaxel
252	Ovarian advanced cARBOplatin and PACLItaxel three weekly
259	Ovarian advanced cARBOplatin and DOCEtaxel
1204	Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin fluorouracil and cetuximab
230	Mesothelioma cARBOplatin and pemetrexed
1470	Non small cell lung cancer metastatic cARBOplatin and weekly PACLItaxel
226	Non small cell lung cancer metastatic cARBOplatin and weekly DOCEtaxel
238	Non small cell lung cancer metastatic cARBOplatin and PACLItaxel
1324	Breast metastatic cARBOplatin and gemcitabine
1010	Ovarian recurrent cARBOplatin and pegylated liposomal DOXOrubicin
1088	Ovarian recurrent cARBOplatin
1680	Ovarian recurrent cARBOplatin and gemcitabine (day 1 cARBOplatin)
260	Ovarian advanced primary treatment cARBOplatin

261	Ovarian recurrent cARBOplatin and gemcitabine (day 8 cARBOplatin) SUPERSEDED
282	Head and neck squamous cell carcinoma locally advanced definitive cARBOplatin and fluorouracil chemoradiation
1208	Nasopharyngeal locally advanced adjuvant cARBOplatin and fluorouracil (following chemoradiation)
280	Head and neck squamous cell carcinoma recurrent or metastatic cARBOplatin and fluorouracil
1432	Non small cell lung cancer metastatic cARBOplatin and gemcitabine
245	Non small cell lung cancer metastatic cARBOplatin and vinORELBine
263	Non small cell lung cancer metastatic cARBOplatin and gemcitabine (day 8 cARBOplatin) SUPERSEDED
215	Small cell lung cancer extensive disease cARBOplatin and etoposide
340	Small cell lung cancer extensive disease cARBOplatin and oral etoposide
374	Small cell lung cancer limited disease cARBOplatin and etoposide
1549	Neuroendocrine advanced cARBOplatin and etoposide
699	Biliary and gallbladder metastatic cARBOplatin and gemcitabine
1021	Bladder/Urothelial small cell cARBOplatin and etoposide
1446	Bladder/Urothelial locally advanced or metastatic cARBOplatin and gemcitabine (day 1 cARBOplatin)
311	Bladder/Urothelial locally advanced or metastatic cARBOplatin and gemcitabine (modified) (day 8 cARBOplatin) SUPERSEDED
325	Testicular germ cell seminoma adjuvant cARBOplatin

## Oxaliplatin

A NK1 receptor antagonist and a 5HT3 receptor antagonist in combination with dexamethasone has been added as available on the PBS for primary prophylaxis of oxaliplatin induced nausea and vomiting.

ID	Protocol name
1674	R-DHAOx (RITUximab dexamethasone cytarabine oxaliplatin)
1672	R-GemOX (RITUximab gemcitabine oxaliplatin)
77	Colorectal adjuvant FLOX (fluorouracil leucovorin oxaliplatin) SUPERSEDED
78	Colorectal adjuvant FOLFOX4 (fluorouracil leucovorin oxaliplatin) SUPERSEDED
17	Colorectal adjuvant FOLFOX4 (modified) (fluorouracil leucovorin oxaliplatin) SUPERSEDED
637	Colorectal adjuvant FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin)
1211	Colorectal adjuvant CAPOX (XELOX) (capecitabine and oxaliplatin)
596	Colorectal metastatic FOLFOX4 (fluorouracil leucovorin oxaliplatin) and bevacizumab SUPERSEDED
102	Colorectal metastatic FOLFOX4 (fluorouracil leucovorin oxaliplatin) SUPERSEDED
107	Colorectal metastatic FOLFOX4 (modified) (fluorouracil leucovorin oxaliplatin) SUPERSEDED
115	Colorectal metastatic FOLFOX6 (fluorouracil leucovorin oxaliplatin) SUPERSEDED
114	Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin)
986	Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and bevacizumab
1542	Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and panitumumab
1534	Colorectal metastatic FOLFOXIRI (modified) (fluorouracil leucovorin oxaliplatin irinotecan)
1715	Colorectal metastatic FOLFOXIRI (modified) (fluorouracil leucovorin oxaliplatin irinotecan)
117	Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin)

1180	Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin) with bevacizumab
1707	Gastric adjuvant CAPOX (XELOX) (capecitabine and oxaliplatin)
1631	Gastric and oesophageal metastatic EOF (epirubicin oxaliplatin fluorouracil) SUPERSEDED
1731	Gastric and oesophageal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin)
528	Gastric and oesophageal metastatic EOX (epirubicin oxaliplatin capecitabine) SUPERSEDED
1704	Oesophageal definitive FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) chemoradiation
1512	Pancreas metastatic FOLFIRINOX (modified) (fluorouracil leucovorin irinotecan oxaliplatin)
1561	Pancreas metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin)
1548	Pancreas metastatic OFF (oxaliplatin fluorouracil leucovorin) SUPERSEDED